BMO Capital Maintains Outperform on Structure Therapeutics, Raises Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman has maintained an Outperform rating on Structure Therapeutics (NASDAQ:GPCR) and raised the price target from $40 to $83.
October 03, 2023 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has maintained an Outperform rating on Structure Therapeutics and raised the price target from $40 to $83.
The news directly pertains to Structure Therapeutics. The raised price target by BMO Capital indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100